The potential of ARL4C and its-mediated genes in atherosclerosis and agent development
Foam cells are the risk factors for atherosclerosis. Recently, ARL4C, a member of the ADP-ribosylation factor family of GTP-binding proteins, was found to promote cholesterol efflux to decrease foam cell formation, suggesting that ARL4C may be a new promising target for the treatment of atherosclero...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1513340/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850278689312342016 |
|---|---|
| author | Dan Liu Jie Wang Shuangshuang Zhang Hongfei Jiang Yudong Wu Chao Wang Wujun Chen Wujun Chen |
| author_facet | Dan Liu Jie Wang Shuangshuang Zhang Hongfei Jiang Yudong Wu Chao Wang Wujun Chen Wujun Chen |
| author_sort | Dan Liu |
| collection | DOAJ |
| description | Foam cells are the risk factors for atherosclerosis. Recently, ARL4C, a member of the ADP-ribosylation factor family of GTP-binding proteins, was found to promote cholesterol efflux to decrease foam cell formation, suggesting that ARL4C may be a new promising target for the treatment of atherosclerosis. In fact, ARL4C regulated the expression of multiple atherosis-related genes, including ABCA1, ALDH1A3, ARF6, ENHO, FLNA, LRP6, OSBPL5, Snail2, and SOX2. Many agents, including ABCA1 agonists (CS-6253, IMM-H007, RG7273, and R3R-01), FLNA antagonist sumifilam, LRP6 inhibitor BI-905677 and agonist SZN-1326, and SOX2 inhibitor STEMVAC, were investigated in clinical trials. Targeting these genes could improve the success rate of drug development in clinical trials. Indeed, many agents could regulate ARL4C expression, including LXR/RXR agonists, Ac-LDL, sucrose, T9-t11-CLA, and miR-26. Downregulation of ARL4C with siRNA and anti-sense oligonucleotide (ASO), such as ASO-1316, is developing in preclinical research for the treatment of lung adenocarcinoma, liver cancer, and colorectal cancer. Thus, ARL4C and its regulated genes may be a potential target for drug development. Thus, we focus on the role of ARL4C and its-mediated genes in atherosclerosis and agent development, which provide insights for the identification, research, and drug development of novel targets. |
| format | Article |
| id | doaj-art-c8d800e4e17741cc8b57bd10eb126d1c |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-c8d800e4e17741cc8b57bd10eb126d1c2025-08-20T01:49:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15133401513340The potential of ARL4C and its-mediated genes in atherosclerosis and agent developmentDan Liu0Jie Wang1Shuangshuang Zhang2Hongfei Jiang3Yudong Wu4Chao Wang5Wujun Chen6Wujun Chen7Guangdong Provincial People’s Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaGuangdong Provincial People’s Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, ChinaAffiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao University, Qingdao, Shandong, ChinaFoam cells are the risk factors for atherosclerosis. Recently, ARL4C, a member of the ADP-ribosylation factor family of GTP-binding proteins, was found to promote cholesterol efflux to decrease foam cell formation, suggesting that ARL4C may be a new promising target for the treatment of atherosclerosis. In fact, ARL4C regulated the expression of multiple atherosis-related genes, including ABCA1, ALDH1A3, ARF6, ENHO, FLNA, LRP6, OSBPL5, Snail2, and SOX2. Many agents, including ABCA1 agonists (CS-6253, IMM-H007, RG7273, and R3R-01), FLNA antagonist sumifilam, LRP6 inhibitor BI-905677 and agonist SZN-1326, and SOX2 inhibitor STEMVAC, were investigated in clinical trials. Targeting these genes could improve the success rate of drug development in clinical trials. Indeed, many agents could regulate ARL4C expression, including LXR/RXR agonists, Ac-LDL, sucrose, T9-t11-CLA, and miR-26. Downregulation of ARL4C with siRNA and anti-sense oligonucleotide (ASO), such as ASO-1316, is developing in preclinical research for the treatment of lung adenocarcinoma, liver cancer, and colorectal cancer. Thus, ARL4C and its regulated genes may be a potential target for drug development. Thus, we focus on the role of ARL4C and its-mediated genes in atherosclerosis and agent development, which provide insights for the identification, research, and drug development of novel targets.https://www.frontiersin.org/articles/10.3389/fphar.2025.1513340/fullatherosclerosischolesterol effluxARL4CABCA1agent development |
| spellingShingle | Dan Liu Jie Wang Shuangshuang Zhang Hongfei Jiang Yudong Wu Chao Wang Wujun Chen Wujun Chen The potential of ARL4C and its-mediated genes in atherosclerosis and agent development Frontiers in Pharmacology atherosclerosis cholesterol efflux ARL4C ABCA1 agent development |
| title | The potential of ARL4C and its-mediated genes in atherosclerosis and agent development |
| title_full | The potential of ARL4C and its-mediated genes in atherosclerosis and agent development |
| title_fullStr | The potential of ARL4C and its-mediated genes in atherosclerosis and agent development |
| title_full_unstemmed | The potential of ARL4C and its-mediated genes in atherosclerosis and agent development |
| title_short | The potential of ARL4C and its-mediated genes in atherosclerosis and agent development |
| title_sort | potential of arl4c and its mediated genes in atherosclerosis and agent development |
| topic | atherosclerosis cholesterol efflux ARL4C ABCA1 agent development |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1513340/full |
| work_keys_str_mv | AT danliu thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT jiewang thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT shuangshuangzhang thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT hongfeijiang thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT yudongwu thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT chaowang thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT wujunchen thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT wujunchen thepotentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT danliu potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT jiewang potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT shuangshuangzhang potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT hongfeijiang potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT yudongwu potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT chaowang potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT wujunchen potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment AT wujunchen potentialofarl4canditsmediatedgenesinatherosclerosisandagentdevelopment |